Celgene Corporation Sustainability Profile
Celgene Corporation, a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for cancer and inflammatory diseases. Founded in 1986, Celgene has achieved significant milestones, including the successful launch of groundbreaking treatments that have transformed patient care. Operating primarily in North America and Europe, Celgene focuses on areas such as oncology, immunology, and haematology. Its core products, including Revlimid and Pomalyst, are renowned for their unique mechanisms of action and efficacy in treating complex conditions. With a strong market position, Celgene has garnered recognition for its commitment to research and development, making substantial contributions to the biopharmaceutical landscape.
DitchCarbon Score
How does Celgene Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celgene Corporation's score of 67 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celgene Corporation, headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which may influence its climate commitments and emissions reporting. As part of its corporate family, Celgene's climate initiatives and targets are likely aligned with those of Bristol-Myers Squibb. However, specific reduction targets or achievements for Celgene itself have not been disclosed. The company does not appear to have set its own Science-Based Targets Initiative (SBTi) reduction targets or other documented reduction initiatives. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints. While Celgene has not provided specific emissions data or reduction commitments, it is essential to monitor the broader initiatives undertaken by its parent company, Bristol-Myers Squibb, which may include significant climate pledges and sustainability goals that could impact Celgene's operations and emissions in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Celgene Corporation's Industry?
How Carbon Intensive is Celgene Corporation's Location?
Celgene Corporation's Scope 3 Categories Breakdown
Celgene Corporation's Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Celgene Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Celgene Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
